Pricing & Access· May 16, 2026 · 8 min readSkyrizi coverage guide: formulary, prior authorization, and patient assistanceSkyrizi (risankizumab-rzaa) is an IL-23 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. This guide maps FDA...By Ran Chen#Immunology#IL-23 Inhibitor#Prior Authorization
